Featured Research

from universities, journals, and other organizations

Novel Targeted Therapy Reduces Chemoresistance In Mouse Model Of Melanoma

Date:
June 17, 2008
Source:
Journal of the National Cancer Institute
Summary:
A novel small molecule inhibitor reduced both endogenous and drug-induced resistance to chemotherapy in a mouse model of melanoma. The NF-κB pathway is often active in human cancers and promotes resistance to cytotoxic chemotherapy drugs. Some cytostatic drugs, such as doxorubicin, induce NF-κB pathway activity.

A novel small molecule inhibitor reduced both endogenous and drug-induced resistance to chemotherapy in a mouse model of melanoma.

The NF-κB pathway is often active in human cancers and promotes resistance to cytotoxic chemotherapy drugs. Some cytostatic drugs, such as doxorubicin, induce NF-κB pathway activity.

To determine if a new inhibitor of the pathway, called KINK-1, could overcome this resistance, Michael Schφn, M.D., of the University Medical Center Gφttingen in Germany and colleagues injected mice with melanoma cells and then treated them with doxorubicin and KINK-1.

They found that mice treated with a combination of the two drugs developed smaller lung metastases than mice treated with either agent alone.

"Based on our observation that the compound suppressed constitutive NF-κB activation and NF-κB activation induced by cytostatics or inflammatory agents, KINK-1 appears to be a universal inhibitor of NF-κB activation in melanoma cells, regardless of the mode of activation," the authors write.

In an accompanying editorial, John Kirkwood, M.D., of the University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute and colleagues review the biology of NF-κB and its impact on melanoma cells. Other inhibitors of the pathway have been tried in melanoma and did not prove successful. The KINK-1 inhibitor blocks the pathway in a different manner and may have a bigger impact on the disease, though that must be tested in a clinical trail. "These new agents may be most beneficially combined with chemotherapeutic agents to which melanoma has been refractory in the past," the editorialists conclude.

This research was recently published in the Journal of the National Cancer Institute.


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Journal of the National Cancer Institute. "Novel Targeted Therapy Reduces Chemoresistance In Mouse Model Of Melanoma." ScienceDaily. ScienceDaily, 17 June 2008. <www.sciencedaily.com/releases/2008/06/080611073244.htm>.
Journal of the National Cancer Institute. (2008, June 17). Novel Targeted Therapy Reduces Chemoresistance In Mouse Model Of Melanoma. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/06/080611073244.htm
Journal of the National Cancer Institute. "Novel Targeted Therapy Reduces Chemoresistance In Mouse Model Of Melanoma." ScienceDaily. www.sciencedaily.com/releases/2008/06/080611073244.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins